Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Granules-India-Ltd"

13 News Found

Supriya Lifescience appoints Krishna Raghunathan as CFO
People | January 24, 2023

Supriya Lifescience appoints Krishna Raghunathan as CFO

He was previously associated with renowned companies such as Granules India Ltd, Dr. Reddy’s Laboratories ltd & Aptar Group

Granules India recalls one batch of Naproxen Sodium 220mg tablets
News | September 13, 2021

Granules India recalls one batch of Naproxen Sodium 220mg tablets

One batch has 11.4 million units of Naproxen tablets out of which 0.9 million units that were released into the market were recalled

Granules India Q1FY22 consolidated net profit at Rs. 120.20 Cr
News | July 28, 2021

Granules India Q1FY22 consolidated net profit at Rs. 120.20 Cr

The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.

Latest Stories

Bristol Myers Squibb presents data across targeted protein degradation research at EHA 2025

AstraZeneca collaborates with CSPC Pharmaceuticals focused on AI-enabled research

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging